Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- NKE +3.9%
Other news:
- LAC +32.4% (reaches agreement with GM and DOE to advance first draw loan)
- CCCC +11.7% (entered into a clinical trial collaboration and supply agreement with Pfizer)
- SLI +6.8% (in sympathy with LAC news)
- PHAR +5.8% (receives FDA acceptance and Priority Review of supplemental NDA for leniolisib)
- VECO +3.5% (Axcelis Tech and Veeco Instruments (VECO) to merge in all-stock transaction)
- BZAI +3.2% (discloses Yotta as end customer)
- ZETA +2.6% (to acquire Marigold's enterprise software unit, reaffirms guidance)
- GEO +2.5% (awarded ICE contract)
- LAR +2.4% (in sympathy with LAC news)
- MSTR +2.4% (increased the regular dividend rate per annum on the Company's Variable Rate Series A Perpetual Stretch Preferred Stock from 10.00% to 10.25% effective for monthly periods commencing on or after October 1, 2025)
- DGNX +2.2% (signs agreements with iNEED for rural banks in Indonesia)
- SGMT +1.7% (doses first participants in Phase 1 PK clinical trial for Denifanstat and Resmetirom combination)
- XPEV +1.4% (Sep deliveries)
- NIO +1.3% (Sep deliveries)
- OPEN +1.1% (Director bought 300752 shares worth ~$2 mln)
- RGP +1% (launches rIQ)
- LI +1% (Sep deliveries)